The medical laboratory plays a key role in ensuring patients with cancer receive the most appropriate treatment. A new evidence-based clinical practice guideline on human epidermal growth factor receptor 2 (HER2) testing for patients with gastroesophageal cancers was recently released by the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and the American Society of Clinical Oncology (ASCO).
The guideline provides recommendations about appropriate HER2 testing for patients at key decision points throughout their cancer therapy to determine if they are eligible for targeted therapy. Check out the video below to learn more about the guideline.
Visit www.ascp.org/HER2gastricguideline to access the new guideline, as well as additional tools and resources.